Apart from a host of branded generic drugs, the company also has plans to launch a few proprietary products from its novel drug delivery system (NDDS) stable as well.
The products to be launched will be in therapeutic areas including the anti-infectives, gastro-intestinal, cardiovascular and central nervous system (CNS).
Ranbaxys newly appointed vice president (pharmaceuticals) and the elder son of late Parvinder Singh, Malvinder Mohan Singh told FE, we have lined up at least 25 new products for the domestic market, which will be launched during the current year. It will help us further beef up our product portfolio in the domestic market.
However, he disagreed that the performance in the domestic market has not been satisfactory.
Mr Singh added, we have outgrown the domestic industry. The industry grew by around 6-7 per cent, we grew by around 10 per cent.
Although the latest ORG figures suggest that the domestic pharma market witnessed a degrowth of five per cent during January, Mr Singh said he disagreed.
At least four of our brands launched last year have managed to be among the top 30 brands, he added. During 2003 the company launched around 18-20 products.
For many of the pharmaceutical companies, the performance in the domestic market has been a cause of concern. They have been devising newer strategies to overcome the slowdown.
Latest ORG figures reveal that companies like Cipla, GlaxoSmithkline, Ranbaxy and Zydus Cadila witnessed a degrowth ranging from 3-7 per cent.
Ranbaxys revenues from India region are around 17 per cent of its total revenues of around $969 million.